{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:53:05Z","timestamp":1781736785867,"version":"3.54.5"},"reference-count":2,"publisher":"Georg Thieme Verlag KG","issue":"09","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Perinatol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This article is a plain language summary of publication (PLSP) of the following articles: \u201cDesign of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA-1)\u201d by Tiller et al published in American Journal of Perinatology on July 28, 2025 (doi:10.1055\/a-2666-5642) and \u201cDesign of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA-3)\u201d by Bussel et al published in American Journal of Perinatology on November 25, 2025 (doi: 10.1055\/a-2753-9323). This PLSP describes the design of the phase 3, placebo-controlled FREESIA-1 and open-label FREESIA-3 trials, which will help researchers understand if nipocalimab, an investigational treatment, can be used to safely treat pregnant individuals who are at risk for fetal and neonatal alloimmune thrombocytopenia (FNAIT). This PLSP will help the general public, including those affected by FNAIT, and health care professionals understand the two studies. It provides information on the eligibility criteria, study design, treatments, and outcomes of interest. An infographic summary of this article is available in the Supplementary Material (available in the online version only).<\/jats:p>","DOI":"10.1055\/a-2761-1775","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:59:56Z","timestamp":1777881596000},"page":"1256-1263","source":"Crossref","is-referenced-by-count":0,"title":["Plain Language Summary of Publication: Design of the Phase 3 FREESIA-1 and FREESIA-3 Trials of Nipocalimab in Fetal and Neonatal Alloimmune Thrombocytopenia"],"prefix":"10.1055","volume":"43","author":[{"given":"Pamela","family":"Baker","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babajide","family":"Keshinro","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Biologics BV, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Stegmann","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbie","family":"Oey","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathye","family":"Shu","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Heerwegh","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Zaha","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary","family":"Van Valkenburgh","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1055\/a-2666-5642","article-title":"Design of a phase 3, multicenter, randomized, placebo-controlled, double-blind study of nipocalimab in pregnancies at risk for fetal and neonatal alloimmune thrombocytopenia","author":"H Tiller","year":"2025","journal-title":"Am J Perinatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1055\/a-2753-9323","article-title":"Design of a phase 3, multicenter, randomized, open-label study of nipocalimab or IVIG and prednisone in pregnancies at risk for fetal and neonatal alloimmune thrombocytopenia","author":"J Bussel","year":"2025","journal-title":"Am J Perinatol"}],"container-title":["American Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2761-1775.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:40:45Z","timestamp":1781736045000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2761-1775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":2,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2026,6,17]]},"published-print":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2761-1775","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0735-1631","1098-8785"],"issn-type":[{"value":"0735-1631","type":"print"},{"value":"1098-8785","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]}}}